Entrada Therapeutics, Inc. (TRDA) Form 8-K — Aug 5, 2026
Entrada Therapeutics reported second quarter 2026 results on August 5, 2026, with collaboration revenue of $0.9 million (down from $2.0 million a year ago), R&D expense of $35.4 million, and a net loss of $42.8 million, or $1.01 per share. Cash, cash equivalents and marketable securities fell to $223.0 million at June 30, 2026 from $295.7 million at year-end 2025, which management says funds operations into the third quarter of 2027 — implying a probable future capital raise.
Key figures
- Revenue
- $0.9 million (Q2 2026 collaboration revenue)
- Guidance
- Cash, cash equivalents and marketable securities sufficient to fund operations into the third quarter of 2027
- Revenue Yoy
- down from $2.0 million in Q2 2025 (~-55%)
- Total Assets
- 298877000
- Cash Position
- 223005000
- Shares Outstanding
- 42221665
- Vx670 Data
- H2 2026 (Vertex GALILEO Phase 1/2 in DM1)
- Cash Runway
- into Q3 2027
- Ga Expense Q2
- $10.5 million (vs $10.9 million in Q2 2025)
- Rnd Expense Q2
- $35.4 million (vs $37.9 million in Q2 2025)
- Six Month Net Loss
- $82.5 million (vs $60.5 million prior-year period)
- Prior Year Net Loss
- $43.1 million (Q2 2025)
- Total Liabilities
- $65.5 million
- Prior Cash Position
- $295.7 million as of December 31, 2025
- Stockholders Equity
- $233.4 million
- Entr60144 Cohort2 Data
- Q1 2027 (12 mg/kg)
- Entr60145 Cohort1 Data
- October 2026 (5 mg/kg MAD)
- Entr60145 Cohort2 Data
- H1 2027 (10 mg/kg MAD)
- Six Month Collaboration Revenue
- $1.8 million (vs $22.5 million prior-year period)
- Entr60144 Cohort1 Open Label Data
- by year-end 2026 (6 mg/kg)
Price after filing
Close on the filing date to close N calendar days later (from $7.24). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.